ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
19 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.3K
|
327K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
51 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1.3K
|
327K
|
51
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
kpax
|
1 |
898 |
4 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1
|
898
|
4
|
|
ASX - By Stock
|
PAA |
NZT gone but hasn't forgotten
|
|
kpax
|
66 |
18K |
62 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
66
|
18K
|
62
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
31K |
20 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
126
|
31K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
31K |
22 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
31K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
31K |
28 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
31K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
kpax
|
317 |
79K |
26 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
317
|
79K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
kpax
|
100 |
26K |
21 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
26K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
22 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.3K
|
327K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
23 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
32 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
32
|
|
ASX - By Stock
|
PAA |
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
36 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.3K
|
327K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
20 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.3K
|
327K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.3K |
327K |
15 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.3K
|
327K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
18 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
38 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
27 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
56 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
56
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
kpax
|
45 |
13K |
35 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
45
|
13K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
kpax
|
197 |
52K |
21 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
197
|
52K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
kpax
|
58 |
15K |
26 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
15K
|
26
|
|
ASX - By Stock
|
PAA |
Best ASX stock Pharmaust for the next 10 years
|
|
kpax
|
9 |
2.6K |
33 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
9
|
2.6K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
kpax
|
197 |
52K |
37 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
197
|
52K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
MY INPUT REGARDING PAA AND SARS-COV-2.
|
|
kpax
|
41 |
9.1K |
12 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
41
|
9.1K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
75K |
20 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
323
|
75K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
75K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
75K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
75K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
75K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
75K |
29 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
75K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
34K |
29 |
28/01/24 |
28/01/24 |
ASX - By Stock
|
111
|
34K
|
29
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
34K |
13 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
111
|
34K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
34K |
16 |
20/01/24 |
20/01/24 |
ASX - By Stock
|
111
|
34K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
34K |
24 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
34K
|
24
|
|
ASX - By Stock
|
PAA |
Sparks Valuation Pharmaust
|
|
kpax
|
111 |
34K |
37 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
34K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
20 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
430
|
107K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
3 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
4 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAAOA Top 20 & Distribution Report
|
|
kpax
|
43 |
11K |
4 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
43
|
11K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.3K |
12 |
05/01/24 |
05/01/24 |
ASX - By Stock
|
18
|
4.3K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.3K |
30 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
18
|
4.3K
|
30
|
|
ASX - By Stock
|
PAA |
Alzheimer's and Monepantel
|
|
kpax
|
18 |
4.3K |
43 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
18
|
4.3K
|
43
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
23 |
01/01/24 |
01/01/24 |
ASX - By Stock
|
430
|
107K
|
23
|
|
ASX - By Stock
|
PAA |
Pharmaust brand name required
|
|
kpax
|
30 |
6.0K |
20 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
30
|
6.0K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
28 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
430
|
107K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
9 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
107K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
8 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
107K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
12 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
107K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
14 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
107K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
kpax
|
430 |
107K |
16 |
02/12/23 |
02/12/23 |
ASX - By Stock
|
430
|
107K
|
16
|
|